Innovation drives China’s weight loss drug market surge

China's weight loss drug market is poised for explosive growth, targeting a 38.3B RMB opportunity as the obese population is set to exceed 300 million by 2030.

While global giants Novo Nordisk and Eli Lilly have entered, they now face a wave of local competition. Innovent's mazdutide is leading the pipeline as the world's first GLP-1R/GCGR dual agonist under NMPA review.

With 56+ local GLP-1 candidates in development, the race is intensifying. Dive into the dynamics of China's weight loss drug surge in our latest VBtalk.

Watch the previous video: Obesity, pharma, and the rise of GLP-1: a market on the verge of explosion